{"page_content": "ESG R eport 2021SAFE HARBOR STATEMENT\nThis communication contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements are \nbased upon the current beliefs and expectations of Agios and are subject to significant risks and uncertainties. For example, there can be no guarantee that \ndevelopment of any of Agios\u2019 product candidates will successfully commence or continue, and there can be no guarantee that any positive developments in \nAgios\u2019 business will result in stock price appreciation. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ \nmaterially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, those related to the impact of the \nCOVID-19 pandemic to Agios\u2019 business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to \nconduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, \nand launching, marketing and selling current or future approved products; Agios\u2019 results of clinical trials and preclinical studies, including subsequent analysis \nof existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory \nauthorities, investigational review boards at clinical trial sites and publication review bodies; Agios\u2019 ability to obtain and maintain requisite regulatory approvals \nand to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios\u2019 ability to obtain, maintain and \nenforce patent and other intellectual property protection for any product candidates it is developing; Agios\u2019 ability to maintain key collaborations; and general \neconomic and market conditions. These and other risks are described in greater detail under the caption \u201cRisk Factors\u201d included in Agios\u2019 public filings with the \nSecurities and Exchange Commission. Any forward-looking statements contained in this communication speak only as of the date hereof, and Agios expressly \ndisclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\nAdditional Information and Where to Find It\nThis communication relates to the proposed transaction involving the sale by Agios Pharmaceuticals, Inc. (\u201cAgios\u201d) of its oncology business to Servier \nPharmaceuticals, LLC. In connection with the proposed transaction, Agios will file relevant materials with the U.S. Securities and Exchange Commission (the \n\u201cSEC\u201d), including Agios\u2019 proxy statement on Schedule 14A (the \u201cProxy Statement\u201d). This communication is not a substitute for the Proxy Statement or any other \ndocument that Agios may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, \nSTOCKHOLDERS OF AGIOS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, WHEN THEY \nBECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be \nable to obtain the documents (when available) free of charge at the SEC\u2019s website, at http://www.sec.gov, and Agios\u2019s website, at www.agios.com. In addition, \nthe documents (when available) may be obtained free of charge by accessing Agios\u2019s website at www.agios.com under the heading \u201cInvestors\u201d or, alternatively, \ndirecting a request to Holly Manning by email at holly.manning@agios.com or by calling 617-649-8600.\nParticipants in the Solicitation\nAgios and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Agios common stock in respect \nof the proposed transaction. Information about the directors and executive officers of Agios is set forth in the proxy statement for Agios\u2019 2020 annual meeting of \nstockholders, which was filed with the SEC on April 16, 2020, and in other documents filed by Agios with the SEC. Other information regarding the participants in \nthe proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other \nrelevant materials to be filed with the SEC in respect of the proposed transaction when they become available. 35", "metadata": {"source": "NASDAQ_AGIO_2020.pdf", "page": 34, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}